Home / Compare / Retatrutide vs Tirzepatide

Retatrutide vs Tirzepatide

Retatrutide vs Tirzepatide: how they work, doses used, FDA status and trial weight loss (28.3% vs 20.9%), with sources.

RetatrutideTirzepatide
Works onGIP + GLP-1 + glucagon (triple agonist)GIP + GLP-1 (dual agonist)
How it is takenInjection, once weeklyInjection, once weekly (Mounjaro, Zepbound)
US statusPhase 3, not approved (filing planned early 2027)FDA-approved (2022 diabetes, 2023 weight)
Highest dose12 mg weekly (highest trial dose)15 mg weekly (label)
Key trialTRIUMPH-1 (phase 3)SURMOUNT-1 (phase 3)
Average weight loss28.3% at 80 weeks (12 mg weekly)20.9% at 72 weeks (15 mg weekly)
Placebo in that trialnot stated in our source3.1%
Not a head-to-head comparison. The weight-loss numbers come from separate trials with different people, doses and lengths. A direct trial is the only way to know which works better.

How they differ

Retatrutide works on gip + glp-1 + glucagon (triple agonist); Tirzepatide works on gip + glp-1 (dual agonist). Retatrutide is taken as: injection, once weekly.Tirzepatide is taken as: injection, once weekly (mounjaro, zepbound).

Dose schedules and warnings: Retatrutide dosage chart ยท Tirzepatide dosage chart.

Questions

Is retatrutide stronger than tirzepatide?
No trial has compared them directly. In separate trials, Retatrutide averaged 28.3% weight loss (TRIUMPH-1 (phase 3), 80 weeks) and Tirzepatide 20.9% (SURMOUNT-1 (phase 3), 72 weeks). Different trials enroll different people over different lengths of time, so the numbers are not a fair head-to-head comparison.
Is retatrutide FDA-approved?
Phase 3, not approved (filing planned early 2027).
Is tirzepatide FDA-approved?
FDA-approved (2022 diabetes, 2023 weight).

Sources

  1. AJMC: Retatrutide achieves up to 30.3% average weight loss in phase 3 TRIUMPH-1
  2. Jastreboff et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). NEJM 2022

Last checked 2026-11-16. How we pick and check sources: methodology.